secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-046792
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025
--------------------------------------------------------------------------------

- Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.
- Net income $1.7M vs loss $1.9M in Q3 2023; adjusted EBITDA $2.8M vs negative $1.2M.
- Cash from operations $4.3M; cash and equivalents $18.3M, up from $11.9M at June 30.
- 2024 guidance raised: net sales $98-101M, gross profit $15-17M, adjusted EBITDA $4-5M.
- Largest customer extended through Dec 2025 but expects volume decline of $31-38M in 2025; company aims to offset with new contracts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828024046792/0001628280-24-046792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828024046792/rmti-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer